Close

Regional variations in US cancer imaging data: a warning for imaging overuse

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals

The Trump administration is preparing to announce a new...

Huawei Expands AI Drug Discovery Ambitions Amid Domestic Chip Push and Policy Support

Huawei intends to deepen its artificial intelligence partnerships with...

McKesson to Acquire Precision Medicine Group for $2.25 Billion

US-based healthcare services provider McKesson has agreed to acquire...
- Advertisement -

Danil V Makarov speaks to Gemma Westcott, Commissioning Editor: Danil V Makarov is an Assistant Professor and Director of Surgical Research in the Department of Urology at NYU Langone Medical Center.

 

In addition, he is an Assistant Professor in the Department of Population Health. His clinical areas of expertise include prostate cancer, benign prostatic hyperplasia, erectile dysfunction, kidney cancer, urinary tract infections, genitourinary neoplasm, elevated prostate-specific antigen and testicular cancer. In addition, his research interests are in the areas of prostate cancer, health policy and quality of care. An alumnus of the Johns Hopkins University School of Medicine (MD, USA), he completed his residency in urology at Johns Hopkins Hospital and a research fellowship at Yale University School of Medicine (CT, USA).

Q Can you tell our readers about your career to date?

I am a urologist and a health services researcher, and I take care of patients with prostate cancer and other urological malignancies clinically. I spend half of my time doing that and I spend the other half of my time doing health services research, which is the intersection between health policy, epidemiology and healthcare economics. I am particularly interested in the cost and quality of care for men with prostate cancer and how those are affected by changes in healthcare policy and the diffusion of new practices and innovations.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals

The Trump administration is preparing to announce a new...

Huawei Expands AI Drug Discovery Ambitions Amid Domestic Chip Push and Policy Support

Huawei intends to deepen its artificial intelligence partnerships with...

McKesson to Acquire Precision Medicine Group for $2.25 Billion

US-based healthcare services provider McKesson has agreed to acquire...

How To Choose A Chemiluminescent Immunoassay Kit?

CLIA stands for chemiluminescent immunoassay. It is a technique...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »